Vir Biotechnology Inc VIR
News
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
Vir Biotechnology's Tobevibart, Elebsiran Combo Gets FDA Fast Track Status for Chronic Hepatitis Delta
Vir Biotechnology, GSK Terminate Collaboration on Flu